MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
29 Septembre 2022 - 3:01PM
Business Wire
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the
“Company”), a targeted therapy, immuno-oncology company focused on
developing potential first-in-class oncology drugs, announced today
that it will present the results of a study of the anticancer agent
6-thio-dG (THIO) in hepatocellular carcinoma (HCC) in vitro and in
vivo models at the EORTC-NCI-AACR (ENA) Symposium on Molecular
Targets and Cancer Therapeutics. The symposium is taking place Oct.
26-28, 2022, in Barcelona, Spain.
The data to be presented outline high anticancer activity of
THIO in HCC cancer cells. Notably, sequential administration of
THIO followed by cemiplimab (cemi) demonstrated enhanced antitumor
efficacy, including complete responses, in a syngeneic
immunocompetent HCC mouse model, in comparison with either single
agent used alone. Moreover, the treated tumor-free mice
demonstrated a complete rejection of the same tumor type cells upon
re-challenge: anticancer immune memory was confirmed.
MAIA received an Orphan Drug Designation from the US FDA for the
treatment of HCC with THIO earlier in 2022. HCC currently makes up
around 90% of liver cancer cases; by 2025, the global incidence of
liver cancer is expected to eclipse 1 million cases.1
Presentation details:
- Presentation title: The novel, telomerase-directed,
telomere-targeted, anticancer agent 6-thio-dG (THIO) demonstrates
potent activity and induces antitumor immunity in hepatocellular
carcinoma (HCC) models
- Abstract number: 86
- Session title: New Drugs
- Date: Wednesday, Oct. 26 at 12:00pm CEST
- Presenting author: Sergei Gryaznov, Ph.D., Chief Scientific
Officer, MAIA Biotechnology
- Location: Exhibition hall
Additional meeting information is available on ENA's
website.
About THIO
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a
telomere-targeting agent currently in clinical development to
evaluate its activity in non-small cell lung cancer (NSCLC), in
sequential administration with cemiplimab (Libtayo®), a PD-1
inhibitor developed by Regeneron. Telomeres play a fundamental role
in the survival of cancer cells and their resistance to current
therapies. THIO is being developed as a second or higher line of
treatment for NSCLC for patients that have progressed beyond the
standard-of-care regimen of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a clinical-stage biopharmaceutical company developing
targeted immunotherapies for cancer. The Company’s lead program is
THIO, a potential first-in-class cancer telomere targeting agent in
clinical development for the treatment of patients with
telomerase-positive cancers. For more information, please visit
www.maiabiotech.com.
1 Llovet, J.M., Kelley, R.K., Villanueva, A. et al.
Hepatocellular carcinoma. Nat Rev Dis Primers 7, 6 (2021).
https://doi.org/10.1038/s41572-020-00240-3
Forward Looking Statements
This press release includes forward-looking statements
including, but not limited to, statements related to the closing of
the offering and the expected use of proceeds, development of drug
candidates, our operations and business strategy, our expected
financial results, and corporate updates. The forward-looking
statements contained in this press release are based on
management’s current expectations and are subject to substantial
risks, uncertainty and changes in circumstances. Actual results may
differ materially from those expressed by these expectations due to
risks and uncertainties, including, among others, those related to
our ability to obtain additional capital on favorable terms to us,
or at all, including, without limitation, to fund our current and
future preclinical studies and clinical trials and the success,
timing and cost of our drug development program and our ongoing or
future preclinical studies and clinical trials, including, without
limitation, the possibility of unfavorable new clinical and
preclinical data and additional analyses of existing data, that the
risks that prior clinical and preclinical results may not be
replicated, and risks associated with the current coronavirus
pandemic. Forward-looking statements speak only as of the date of
this press release, and we undertake no obligation to review or
update any forward-looking statement except as may be required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220929005574/en/
Investor Inquiries MAIA Biotechnology Joseph McGuire
Chief Financial Officer jmcguire@maiabiotech.com 904-228-2603 ICR
Westwicke Stephanie Carrington Stephanie.carrington@westwicke.com
646-277-1282 Media Inquiries ICR Westwicke Sean Leous
Sean.leous@westwicke.com 646-866-4012
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024